Genes Potentially Associated with Familial Hypercholesterolemia.

Area of Science:

• Genetics
• Biochemistry
• Metabolic Disorders

Background:

• Familial hypercholesterolemia (FH) pathogenesis involves low-density lipoprotein receptor (LDLR) variants and associated ligands (Apolipoprotein B, PCSK9, LDLRAP1).
• Lipid abnormalities, including sphingolipids, fatty acids, and sterols, also contribute to FH.
• Genetic causes remain unidentified in 20%-40% of FH cases, highlighting the need for further research.

Purpose of the Study:

• To review the contribution of specific genes to the phenotype of familial hypercholesterolemia.
• To identify novel genetic targets for improved diagnosis and personalized management of FH.
• To explore the role of lipid metabolism aberrations in FH etiology.

Main Methods:

• Literature review of genetic and molecular mechanisms underlying familial hypercholesterolemia.
• Analysis of current understanding of LDLR pathway and lipid metabolism in FH.
• Evaluation of emerging gene targets implicated in lipid metabolism.

Main Results:

• Established genetic factors and lipid dysregulation are key in FH.
• Genes such as STAP1, CYP7A1, LIPA, ABCG5, ABCG8, and PNPLA5 are implicated in lipid metabolism aberrations.
• These genes represent potential new diagnostic and therapeutic targets for FH.

Conclusions:

• Understanding the genetic basis of FH is crucial for effective management.
• Investigating novel genes involved in lipid metabolism offers promise for personalized FH treatments.
• Further research into STAP1, CYP7A1, LIPA, ABCG5, ABCG8, and PNPLA5 could advance FH diagnosis and therapy.